IDC FutureScape: Worldwide Life Sciences 2025 Predictions

IDC FutureScape Figure

• Figure: IDC FutureScape: Worldwide Life Sciences 2025 Top 10 Predictions

Executive Summary

IDC FutureScape Predictions

• Summary of External Drivers

• Predictions: Impact on Technology Buyers

• Prediction 1: By 2025, 50% of Life Sciences Firms with Cohesive Data Strategies Mitigating Data Debt, Data Quality, and Sovereignty Issues to Support GenAI Will Achieve 30% Faster Time to Market than Those Without

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 2: By 2026, 75% of Pharmas Will Have Established AI Ethics Boards, Including Digital Ethicists, Legal/Regulatory Experts, and Patients, to Build Responsible AI Frameworks and Design Ethical AI Solutions

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 3: By the End of 2026, 75% of Big Pharmas and Biotechs Will Leverage AI-Enabled Radiology and Pathology Solutions to Fuel R&D, Powered by Innovative Medical Device Companies and Global CROs

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 4: By 2027, GenAI Will Power 65% of Drug Discovery and 85% of Both R&D Content Development and Sales and Marketing Initiatives in Pharma, Supported by Evolving Regulations and Focused Investments

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 5: By 2027, at Least 50% of HCPs in Complex Medical Specialties Will Forgo GenAI-Based Drug Prescription Suggestions About Concerns About Training Content Source Transparency and Patient Anxiety

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 6: By 2027, 70% of Medical Device Firms Will Form Deeper Alliances with AI-Driven Cybersecurity Vendors, Fueled by the Evolving Demand for End-to-End Security and Patient Safety by Design in Healthcare

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 7: By 2028, 100% of Pharma and Medical Device Firms Will Adopt Digital Strategies to Manifest Environmental Stewardship and Apply Ecodesign and Green Chemistry Principles to R&D Processes and Products

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 8: Investments in Synthetic Data by Pharma Will Triple by 2029 to Train Foundation Models, Transform Clinical Trial Design, Accelerate R&D Innovation, and Fuel Growth

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 9: By the End of 2029, 40% of Cell and Gene Therapy Firms Will Embed Manufacturing Capabilities in Hospitals, Shortening Supply Chains and Improving Patient Access to Treatment Centers and Labs

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

• Prediction 10: By 2030, 30% of Life Sciences Firms Will Scale from Digital Twins of Entities to Digital Twins of Humans, Moving from Egosystems to Ecosystems, Scaling the Growth of Safer Precision Therapies by 50%

• Associated Drivers

• IT Impact

• Patient Impact

• Guidance

Advice for Technology Buyers

External Drivers: Details

• AI-Driven Business Models — Moving from AI Experimentation to Monetization

• The Drive to Automate — Toward a Data-Driven Future

• AI-Driven Workplace Transformation — Building Tomorrow's Workforce Today

• Regulatory Flux — Navigating Compliance Challenges in a Shifting Policy Landscape

• Expanding Digital Security Frontiers — Fortification Against Multiplying Threats

• Responsible and Human-Centric Technology — Ethics in the Enterprise

• Customer Experience Squared — Consumer and Citizen Expectations for Digital Services

Learn More

• Related Research